Hematopoietic stem cell transplantation.

541 01. Which of the following newly diagnosed patients is most likely to be considered for an allogeneic hematopoietic stem cell transplant (HSCT)? a. Mr. Williams, a 23-year-old with acute leukemia b. Mrs. Smith, a 45-year-old with breast cancer c. Mr. Henderson, a 54-year-old with multiple myeloma d. Ms. Elliott, a 36-year-old with Hodgkin lymphoma 02. Mrs. Johnston is being evaluated for HSCT. Mr. Johnston states that he has done quite a bit of Internet-based research about stem cell transplants and asks you what the main disadvantage of an autologous HSCT is over an allogeneic HSCT. Your response is based on the fact that autologous HSCTs have a a. Higher treatment-related mortality. b. Higher incidence of graft-versushost disease (GVHD). c. Delayed return of normal bone marrow function. d. Higher incidence of mortality from recurrent disease. 03. Which of the following antigens is consistently present on all hematopoietic stem cells? a. CD3 b. CD4 c. CD8 d. CD34 04. To enhance the reconstitution of the immune system following an allogeneic HSCT, the recipient and donor primarily are matched for a. Gender. b. ABO compatibility. c. Cytomegalovirus (CMV) antigen. d. Human leukocyte antigens (HLAs). 05. A nonmyeloablative as compared to a myeloablative HSCT would involve administration of chemotherapy and/or radiotherapy resulting in a. Severe myelosuppression. b. Lower incidence of GVHD. Margaret Bevans, RN, MS, AOCN®, and Nonniekaye Shelburne, RN, MS, AOCN®, are clinical nurse specialists at the National Institutes of Health Clinical Center in Bethesda, MD. (Mention of specific products and opinions related to those products do not indicate or imply endorsement by the Clinical Journal of Oncology Nursing or the Oncology Nursing Society.)